Dec 15 2012
Biopharmaceutical company Endocyte has selected the Medidata Solutions (NASDAQ: MDSO) cloud-based platform to support the execution of multiple ongoing clinical trials focused on the development of targeted therapies for cancer and other serious diseases. Endocyte has a rich pipeline of drugs in clinical development, including proprietary technology for ovarian and lung cancer indications. The company recently filed for commercial authorization in the European Union (EU) for one treatment aimed at addressing a form of ovarian cancer. Endocyte is implementing the combined solution of Medidata's electronic data capture (EDC) and clinical data management (CDM) system Medidata Rave® along with Medidata CTMS™.
“The Medidata Clinical Cloud is designed to accelerate trials, while reducing both cost and risk”
-
"The Medidata Clinical Cloud will allow us to maintain streamlined operations and efficient execution of our ongoing clinical trials," said Hong Ma, director of clinical operations, Endocyte. "This will ensure that we obtain the highest level of data quality and integrity."
Endocyte is taking advantage of one of Medidata's core competencies—quick migration of existing trial data from other systems into the standards-based Medidata platform. Endocyte is using Medidata Rave to ensure high quality and integrity of captured patient data, and Medidata CTMS to streamline operations. With the unique benefits offered by the Medidata Clinical Cloud, including the seamless flow of study data between the Medidata Rave EDC/CDM system and Medidata CTMS, Endocyte will benefit from a continued high level of study data accuracy and streamlined trial execution.
-
"The Medidata Clinical Cloud is designed to accelerate trials, while reducing both cost and risk," said Glen de Vries, president, Medidata Solutions. "Embracing Medidata's platform will bring continued efficiency to the development of Endocyte's rich pipeline."
SOURCE Medidata Solutions
Researchers uncover key genes linked to DCIS progression